Despite relatively high variability in tumor burden in the PBS group, significant antitumor activity was observed with the GalNAc-conjugated MyD88 ASO, with 10 of 16 animals being tumor free compared to the PBS group where only two animals had no tumors (p < 0.05) (Figure 6B). This evidence concerns the gene MYD88 and neoplasm.